Search PubMed⌕ Search

Biomedical subjects

C Ponticelli

Publications and source records attributed to C Ponticelli.

371 records · Page 21Linked to original sources
PubMedDate not supplied

Comparison of three different tests for assessment of hepatitis C virus in dialysis patients.

OBJECTIVE: To evaluate the relationship between hepatitis C virus antibodies (HCV-Ab) and viremia and to compare the prevalence of HCV-Ab and HCV viremia in hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) patients. DESIGN: Cross-sectional study. SETTING: Dialysis unit of a nephrology division in a public university hospital. PATIENTS: All dialysis patients who came for routine clinic visits during the study period. None denied informed consent. Forty-eight patients on HD and 79 on CAPD were examined. INTERVENTION: Blood samples were tested by second-generation enzyme-linked immunosorbent assay (ELISA II) and recombinant immunoblot assay (RIBA II) to look for HCV-Ab and by the polymerase chain reaction (PCR) to look for HCV viremia. RESULTS: ELISA II was positive in 52% of HD patients and in 14% of CAPD patients. RIBA II was positive in 48% of HD patients and in 11% of CAPD patients. HCV viremia was positive by PCR in 41.6% of HD patients and in 12% of CAPD patients. Two of these PCR-positive patients did not show HCV-Ab by ELISA II and RIBA II. The sensitivity and specificity of ELISA II were 93% and 92%, the sensitivity and specificity of RIBA II were 86% and 94%. CONCLUSIONS: Our data confirm a higher prevalence of HCV viremia in HD than in CAPD patients. The absence of Ab against virus C in 2 patients positive with PCR might be due to recent HCV infection or to weak virus replication or to a poor immune response.

Alanine Transaminase↗
PubMedDate not supplied

[Renal amyloidosis].

Explore the source record for details and available documents.

Amyloidosis↗
PubMedDate not supplied

Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients.

We carried out an open, randomized, cross-over study to test the rationale for use of a low molecular weight heparin during hemodialysis with polysulphone membranes. Ten uremic patients (6 men, 4 women, mean age 50 +/- 11 years, range 31-70) in chronic hemodialysis underwent paired filtration dialysis with either low molecular weight heparin or unfractionated heparin, then crossed over to the other anticoagulant treatment. We measured the following: anti-factor Xa and anti-factor IIa activity in patients' plasma and in the ultrafiltrate, activated partial thromboplastin time and bleeding time before, during and after hemodialysis. Some low molecular weight fractions of heparin were lost in the ultrafiltrate during hemodialysis, while higher molecular weight fractions were retained. The activated partial thromboplastin time during dialysis and the bleeding time after dialysis were more prolonged with unfractionated heparin than with the low molecular weight heparin (p < 0.01 and p < 0.05 respectively). Our data indicate that the use of a low molecular weight heparin determines a less pronounced prolongation of the activated partial thromboplastin time during dialysis and prevents a post-dialytic increase in bleeding time.

Adult↗